Spyre Therapeutics Inc. (SYRE)
12.78
-1.21 (-8.65%)
At close: Apr 04, 2025, 3:59 PM
12.79
0.08%
After-hours: Apr 04, 2025, 04:20 PM EDT
-8.65% (1D)
| Bid | 12.31 |
| Market Cap | 770.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.18 |
| PE Ratio (ttm) | -4.02 |
| Forward PE | -5.21 |
| Analyst | Buy |
| Ask | 13.37 |
| Volume | 1,483,736 |
| Avg. Volume (20D) | 648,788 |
| Open | 13.19 |
| Previous Close | 13.99 |
| Day's Range | 12.56 - 13.63 |
| 52-Week Range | 12.56 - 40.84 |
| Beta | 3.06 |
About SYRE
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates desig...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2016
Employees 65
Stock Exchange NASDAQ
Ticker Symbol SYRE
Website https://www.spyre.com
Analyst Forecast
According to 7 analyst ratings, the average rating for SYRE stock is "Buy." The 12-month stock price forecast is $45, which is an increase of 252.11% from the latest price.
Stock ForecastsNext Earnings Release
Spyre Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-8.97%
Spyre Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
